Anika Therapeutics, Inc. AKP.F Stock
Anika Therapeutics, Inc. Price Chart
Anika Therapeutics, Inc. AKP.F Financial and Trading Overview
Anika Therapeutics, Inc. stock price | 23.8 EUR |
Previous Close | 24.8 EUR |
Open | 24.2 EUR |
Bid | 24.4 EUR x 100000 |
Ask | 24.6 EUR x 100000 |
Day's Range | 24.2 - 24.2 EUR |
52 Week Range | 20.8 - 31.2 EUR |
Volume | 250 EUR |
Avg. Volume | 4 EUR |
Market Cap | 357.12M EUR |
Beta (5Y Monthly) | 0.835563 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.26 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 49.67 EUR |
AKP.F Valuation Measures
Enterprise Value | 316.63M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | 15.74 |
Price/Sales (ttm) | 2.2679307 |
Price/Book (mrq) | 1.285115 |
Enterprise Value/Revenue | 2.011 |
Enterprise Value/EBITDA | -29.374 |
Trading Information
Anika Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 0.835563 |
52-Week Change | 17.75% |
S&P500 52-Week Change | 20.43% |
52 Week High | 31.2 EUR |
52 Week Low | 20.8 EUR |
50-Day Moving Average | 24.65 EUR |
200-Day Moving Average | 26.39 EUR |
AKP.F Share Statistics
Avg. Volume (3 month) | 4 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 14.76M |
Float | 12.88M |
Short Ratio | N/A |
% Held by Insiders | 2.36% |
% Held by Institutions | 91.04% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -14.14% |
Operating Margin (ttm) | -16.0030% |
Gross Margin | 62.11% |
EBITDA Margin | -6.84% |
Management Effectiveness
Return on Assets (ttm) | -4.62% |
Return on Equity (ttm) | -7.90% |
Income Statement
Revenue (ttm) | 157.47M EUR |
Revenue Per Share (ttm) | 10.78 EUR |
Quarterly Revenue Growth (yoy) | 3.40% |
Gross Profit (ttm) | 96.78M EUR |
EBITDA | -10779000 EUR |
Net Income Avi to Common (ttm) | -22276000 EUR |
Diluted EPS (ttm) | -1.4 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 79.74M EUR |
Total Cash Per Share (mrq) | 5.4 EUR |
Total Debt (mrq) | 30.39M EUR |
Total Debt/Equity (mrq) | 10.95 EUR |
Current Ratio (mrq) | 5.588 |
Book Value Per Share (mrq) | 18.831 |
Cash Flow Statement
Operating Cash Flow (ttm) | 2.66M EUR |
Levered Free Cash Flow (ttm) | 2.26M EUR |
Profile of Anika Therapeutics, Inc.
Country | Germany |
State | MA |
City | Bedford |
Address | 32 Wiggins Avenue |
ZIP | 01730 |
Phone | 781 457 9000 |
Website | https://www.anikatherapeutics.com |
Industry | Medical Devices |
Sector(s) | Healthcare |
Full Time Employees | 345 |
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Q&A For Anika Therapeutics, Inc. Stock
What is a current AKP.F stock price?
Anika Therapeutics, Inc. AKP.F stock price today per share is 23.8 EUR.
How to purchase Anika Therapeutics, Inc. stock?
You can buy AKP.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Anika Therapeutics, Inc.?
The stock symbol or ticker of Anika Therapeutics, Inc. is AKP.F.
Which industry does the Anika Therapeutics, Inc. company belong to?
The Anika Therapeutics, Inc. industry is Medical Devices.
How many shares does Anika Therapeutics, Inc. have in circulation?
The max supply of Anika Therapeutics, Inc. shares is 14.85M.
What is Anika Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Anika Therapeutics, Inc. PE Ratio is now.
What was Anika Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Anika Therapeutics, Inc. EPS is -5.26 EUR over the trailing 12 months.
Which sector does the Anika Therapeutics, Inc. company belong to?
The Anika Therapeutics, Inc. sector is Healthcare.